AR116426A1 - Composición de anticuerpos anti-tfpi de alta eficiencia - Google Patents

Composición de anticuerpos anti-tfpi de alta eficiencia

Info

Publication number
AR116426A1
AR116426A1 ARP190102643A ARP190102643A AR116426A1 AR 116426 A1 AR116426 A1 AR 116426A1 AR P190102643 A ARP190102643 A AR P190102643A AR P190102643 A ARP190102643 A AR P190102643A AR 116426 A1 AR116426 A1 AR 116426A1
Authority
AR
Argentina
Prior art keywords
tfpi antibody
composition
antibody
tfpi
high efficiency
Prior art date
Application number
ARP190102643A
Other languages
English (en)
Inventor
Yuna Kim
Ji Yoon Park
Haeng Eun Song
Geun Hye Yeo
Min Jung Kim
Original Assignee
Green Cross Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp filed Critical Green Cross Corp
Publication of AR116426A1 publication Critical patent/AR116426A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Water Supply & Treatment (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación se relaciona con una composición farmacéutica de anticuerpos anti-TFPI de alta eficacia que incluye un anticuerpo anti-TFPI para tratar la hemofilia, en el que el contenido de HCP en una sustancia farmacéutica es menor a 10,0 ng/mg, y el contenido de LPA en la sustancia farmacéutica o el producto farmacéutico es de menos de 1,0 ng/mg. De acuerdo con la presente divulgación, una composición de anticuerpos anti-TFPI de alta eficiencia con contenidos muy bajos de HCP y LPA puede proporcionarse al proporcionar un proceso de separación / purificación que puede minimizar la generación de polímeros de anticuerpos anti-TFPI, y puede utilizarse de manera efectiva para el tratamiento de pacientes con hemofilia inducida por anticuerpos y para la prevención de coagulopatías.
ARP190102643A 2018-09-21 2019-09-18 Composición de anticuerpos anti-tfpi de alta eficiencia AR116426A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020180113974A KR102337683B1 (ko) 2018-09-21 2018-09-21 고효율 항-tfpi 항체 조성물

Publications (1)

Publication Number Publication Date
AR116426A1 true AR116426A1 (es) 2021-05-05

Family

ID=69887465

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102643A AR116426A1 (es) 2018-09-21 2019-09-18 Composición de anticuerpos anti-tfpi de alta eficiencia

Country Status (14)

Country Link
US (1) US20220025067A1 (es)
EP (1) EP3853259A4 (es)
JP (2) JP7419355B2 (es)
KR (1) KR102337683B1 (es)
CN (1) CN112771081A (es)
AR (1) AR116426A1 (es)
AU (1) AU2019342637B2 (es)
BR (1) BR112021005273A2 (es)
CA (1) CA3111179A1 (es)
EA (1) EA202190825A1 (es)
MX (1) MX2021003143A (es)
MY (1) MY198049A (es)
TW (1) TWI738054B (es)
WO (1) WO2020060087A1 (es)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070072510A (ko) * 2004-08-30 2007-07-04 론자 바이올로직스 피엘씨 항체 정제를 위한 친화도- 및 이온 교환- 크로마토그래피
TW201333030A (zh) * 2006-04-05 2013-08-16 Abbott Biotech Ltd 抗體之純化
TW201024318A (en) * 2008-10-20 2010-07-01 Abbott Lab Isolation and purification of antibodies using protein A affinity chromatography
DK2379600T4 (da) * 2008-12-22 2021-01-04 Novo Nordisk As Antistoffer mod tissue factor pathway inhibitor
AU2010253830B2 (en) * 2009-05-27 2016-03-03 Takeda Pharmaceutical Company Limited A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
SI3409289T1 (sl) * 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
USRE47150E1 (en) * 2010-03-01 2018-12-04 Bayer Healthcare Llc Optimized monoclonal antibodies against tissue factor pathway inhibitor (TFPI)
EP2547355B1 (en) * 2010-03-19 2017-01-11 Baxalta GmbH Tfpi inhibitors and methods of use
EP2571892A2 (en) * 2010-05-18 2013-03-27 AbbVie Inc. Apparatus and process of purification of proteins
BR112012030139A2 (pt) * 2010-05-28 2017-06-13 Novo Nordisk As composições estáveis de anticorpos de doses múltiplas compreendendo um anticorpo e um preservante
PT2864346T (pt) * 2012-06-21 2018-12-12 Synthon Biopharmaceuticals Bv Método de purificação de um anticorpo
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
TW201522368A (zh) * 2013-03-15 2015-06-16 Bayer Healthcare Llc 抗組織因子路徑抑制劑之前藥抗體
HUE057119T2 (hu) * 2013-05-06 2022-04-28 Sanofi Sa Folyamatos többlépéses eljárás antitestek tisztítására
AR096713A1 (es) * 2013-06-25 2016-01-27 Cadila Healthcare Ltd Proceso de purificación para anticuerpos monoclonales
EP3066123A1 (en) * 2013-11-07 2016-09-14 AbbVie Inc. Isolation and purification of antibodies
CN106029682B (zh) * 2013-12-27 2021-04-13 中外制药株式会社 等电点低的抗体的纯化方法
EP2982692A1 (en) * 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
KR101804988B1 (ko) 2015-09-24 2017-12-07 재단법인 목암생명과학연구소 신규 항-tfpi 항체 및 이를 포함하는 조성물
KR101744899B1 (ko) * 2015-02-25 2017-06-08 재단법인 목암생명과학연구소 신규 항-tfpi 항체 및 이를 포함하는 조성물
EP3262075B1 (en) * 2015-02-25 2024-03-13 Mogam Institute For Biomedical Research Novel antibody binding to tfpi and composition comprising the same
KR102068915B1 (ko) * 2015-08-19 2020-01-22 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
CA3027457A1 (en) * 2016-06-17 2017-12-21 Portola Pharmaceuticals, Inc. Preparation of factor xa derivatives

Also Published As

Publication number Publication date
BR112021005273A2 (pt) 2021-06-15
AU2019342637B2 (en) 2024-04-18
WO2020060087A1 (en) 2020-03-26
CN112771081A (zh) 2021-05-07
CA3111179A1 (en) 2020-03-26
JP2022501379A (ja) 2022-01-06
TWI738054B (zh) 2021-09-01
JP2024020287A (ja) 2024-02-14
EP3853259A4 (en) 2022-06-15
US20220025067A1 (en) 2022-01-27
MX2021003143A (es) 2021-05-14
TW202017596A (zh) 2020-05-16
EA202190825A1 (ru) 2021-06-17
AU2019342637A1 (en) 2021-05-13
MY198049A (en) 2023-07-28
JP7419355B2 (ja) 2024-01-22
KR102337683B1 (ko) 2021-12-13
EP3853259A1 (en) 2021-07-28
KR20200034321A (ko) 2020-03-31

Similar Documents

Publication Publication Date Title
ATE449602T1 (de) Arzneimittel mit dobesilat-calcium zur behandlung und prophylaxe von sehnenerkrankungen
JP2017048208A5 (es)
AR050418A1 (es) Dosificacion fija de anticuerpos her
CO6311006A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altas
MX2019012884A (es) Terapia de combinacion.
CO6280475A2 (es) Metodo para tratar la deficiencia de vitamina b12
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
ATE318133T1 (de) Verwendung von stearidonsäure zur herstellung eines arzneimittels für die behandlung oder vorbeugung von krebs
SE0950390L (sv) System och process för tillverkning av en lösning med suspenderade fasta ämnen och användningar därför
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
MY153932A (en) A medicinal product and treatment
AR098832A1 (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
ZA201905212B (en) Rescue treatment of post operative nausea and vomiting
AR116426A1 (es) Composición de anticuerpos anti-tfpi de alta eficiencia
MX2022005388A (es) Compuestos de pirrolidina y piperidina.
MX2022015232A (es) Composicion farmaceutica acuosa de levilimab y su uso.
FI3630177T3 (fi) Hoitoparadigma anti-cd19-vasta-aineen ja venetoklaksin yhdistelmähoidolle
BR112018068784A2 (pt) método para o tratamento de leucemia
ECSP21060962A (es) Composiciones farmacéuticas que comprenden meloxicam
MX2022012001A (es) Tratamiento preventivo de la migra?a.
BR112018002433A2 (pt) composição farmacêutica para tratamento da enxaqueca
AR108792A1 (es) Composiciones que comprenden timolol
RU2013154562A (ru) Способы и композиции для сохранения безжировой массы тела в процессе похудения
AR101227A1 (es) Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor
AR100153A1 (es) Medicamento